Recently, Anderson et al [
[1]
] reported on the generalizability of trials supporting the 2017 American College of
Cardiology/American Heart Association blood pressure guideline. They are correct when
concluding that SPIRIT and ACCORD, the clinical trials underlying new treatment thresholds,
were not representative for more than two-thirds of the target population. Yet, as
the authors did [
- Anderson TS
- Odden M
- Penko J
- et al.
Generalizability of Clinical Trials supporting the 2017 American College of Cardiology/American
Heart Association Blood Pressure Guideline.
JAMA Intern Med. 2020 Mar 16; (Epub ahead of print)https://doi.org/10.1001/jamainternmed.2020.0051
[1]
], in these two sentences two concepts have been used as if they were interchangeable:
generalizability and representativeness.- Anderson TS
- Odden M
- Penko J
- et al.
Generalizability of Clinical Trials supporting the 2017 American College of Cardiology/American
Heart Association Blood Pressure Guideline.
JAMA Intern Med. 2020 Mar 16; (Epub ahead of print)https://doi.org/10.1001/jamainternmed.2020.0051
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Generalizability of Clinical Trials supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline.JAMA Intern Med. 2020 Mar 16; (Epub ahead of print)https://doi.org/10.1001/jamainternmed.2020.0051
- Porta M A dictionary of epidemiology. Oxford University Press, New York2014
- Improving the reporting of pragmatic trials: an extension of the CONSORT statement.BMJ. 2008; 337 (a2390)
- Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?.BMC Med. 2018; 16: 49
- The PRECIS-2 tool: designing trials that are fit for purpose.BMJ. 2015; 350 (h2147)
- Efficacy and effectiveness: The wrong use of different terms.Eur J Intern Med. 2018; 54 (e17-8)
Article info
Publication history
Published online: April 18, 2020
Accepted:
April 3,
2020
Received:
March 27,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
